Concepedia

Publication | Closed Access

Phase I Safety and Pharmacokinetic Study of CT-011, a Humanized Antibody Interacting with PD-1, in Patients with Advanced Hematologic Malignancies

DOI

692

Citations

11

References

2008

Year

Raanan Berger, Rinat Rotem‐Yehudar, Gideon Slama, Shimon Landes, Abraham Kneller, Merav Leiba, Maya Koren‐Michowitz, Avichai Shimoni, Arnon Nagler
Clinical Cancer Research

Abstract

A single administration of 0.2 to 6.0 mg/kg of CT-011 is safe and well tolerated in patients with advanced hematologic malignancies.

References

YearCitations

Page 1